Anti-PD-1 and regorafenib induce severe multisystem adverse events in microsatellite stability metastatic colorectal cancer: a case report.
Sign Up to like & getrecommendations! Published in 2021 at "Immunotherapy"
DOI: 10.2217/imt-2020-0327
Abstract: There exists a dilemma in the treatment of microsatellite stability (MSS) metastatic colorectal cancer (mCRC) owing to limited therapeutic options. Based on the promising results of the REGONIVO trial, combination of anti-PD-1 and regorafenib could… read more here.
Keywords: metastatic colorectal; anti regorafenib; microsatellite stability; colorectal cancer ... See more keywords
Low-dose immunogenic chemotherapeutics promotes immune checkpoint blockade in microsatellite stability colon cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.1040256
Abstract: More than 85% of colorectal cancer (CRC) patients, who are with microsatellite stability (MSS), are resistant to immune checkpoint blockade (ICB) treatment. To overcome this resistance, combination therapy with chemotherapy is the most common choice.… read more here.
Keywords: immune checkpoint; tigit blockade; blockade; checkpoint blockade ... See more keywords